Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy

This publication has 14 references indexed in Scilit:

• Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil
  Translational Research, 2006
• IN VITRO BLOOD DISTRIBUTION AND PLASMA PROTEIN BINDING OF THE IRON CHELATOR DEFERASIROX (ICL670) AND ITS IRON COMPLEX FE-[ICL670]2 FOR RAT, MARMOSET, RABBIT, MOUSE, DOG, AND HUMAN
  Drug Metabolism and Disposition, 2006
• Iron chelation therapy.
  2005
• Thalassemia
  Hematology-American Society Hematology Education Program, 2004
• Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia.
  2003
• Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial
  The Lancet, 2003
• ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture
  Blood, 2001
• Survival and Disease Complications in Thalassemia Major
  Annals of the New York Academy of Sciences, 1998
• High Incidence of Cardiomyopathy in Beta-Thalassaemia Patients Receiving Regular Transfusion and Iron Chelation: Reversal by Intensified Chelation
  Acta Haematologica, 1990
• Chelation Therapy and Cardiac Status in Older Patients with Thalassemia Major
  Journal of Pediatric Hematology/Oncology, 1990